New blood test screening targets hidden cancer in black communities

NCT ID NCT05831358

Ongoing Diagnosis Sponsor: Case Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a blood screening program to find multiple myeloma and its early stages (MGUS and smoldering myeloma) in Black adults aged 50 and older. Participants get a simple blood test and fill out questionnaires about their experience and knowledge of the disease. Those with abnormal results receive help navigating follow-up care. The goal is to see if community-based screening and patient navigation can improve early detection and reduce cancer disparities.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: blood test for monoclonal protein analysis
What this could lead to: If successful, this screening program could help detect multiple myeloma earlier in high-risk communities, potentially improving outcomes and reducing health disparities.
What could go wrong: This is a small pilot study focused on feasibility and community reception, not on proving that screening saves lives. It may not show a clear benefit or be scalable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

monoclonal gammopathy of uncertain significance plasma cell myeloma Smoldering Multiple Myeloma smoldering plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE MULTIPLE MYELOMA SMOLDERING MULTIPLE MYELOMA

Contacts and locations

Locations

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.